Clinical trials
HER2 + Breast Cancer clinical trials
Below are recruiting her2 + breast cancer clinical trials, each written for real people, not researchers. We’re tracking 956 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03730922Recruiting
Delayed vs immediate breast reconstruction after mastectomy and radiation
This study compares two timing options for rebuilding the breast after mastectomy followed by radiation: a reconstruction done later (delayed) versus one done sooner (delayed-immediate). The goal is to see which approach works better and is safer for recovery after treatment.
AabenraaAges 18 years+ - NCT06966388RecruitingPhase 1
Azelaic acid cream for breast cancer patients during radiation
This study tests whether using a topical azelaic acid cream twice daily during radiation therapy is feasible for breast cancer patients. The cream may help reduce skin side effects from radiation, and the study focuses on people with certain skin types that tan easily or have more pigment.
Richmond, VirginiaAges 18 years+ - NCT04427293RecruitingPhase 1
Testing lenvatinib and pembrolizumab before breast cancer surgery
This early-phase trial tests whether lenvatinib plus pembrolizumab given before surgery can help treat early-stage triple-negative breast cancer. If you qualify, you would receive study medicines before your planned operation to remove the tumor and nearby lymph nodes.
Chicago, IllinoisAges 18 years+ - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Birmingham, AlabamaAges 50–70 - NCT04985058Recruiting
Study of abemaciclib plus hormone therapy in breast cancer
This study uses real-world health records to learn about outcomes in people with hormone-receptor positive, HER2-negative breast cancer who were treated with abemaciclib along with hormone (endocrine) therapy. It may help doctors better understand how well this treatment works outside of clinical trials.
AthensAges 18 years+ - NCT05076682RecruitingPhase 2
Study for hard-to-treat triple-negative breast cancer that keeps growing
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
ShanghaiAges 18–70 - NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75 - NCT05806060RecruitingPhase 3
Targeted first treatment for a rare TNBC subtype with spread
This Phase 3 trial tests a more precise treatment strategy for a specific rare type of triple-negative breast cancer (TNBC) called the BLIS subtype. It’s for people whose cancer has spread or cannot be fully removed and who have not had chemo or targeted therapy for metastatic TNBC yet.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06309290Recruiting
Prehabilitation with strength training before breast cancer treatment
This trial tests if strength exercises before starting chemotherapy can help postmenopausal women with breast cancer. It aims to improve patients' ability to undergo treatment and surgery.
SantiagoAges Any age - NCT06355037RecruitingPhase 2
Dasatinib and quercetin for chemo-resistant triple negative breast cancer
This trial tests whether adding dasatinib and quercetin to your treatment can reverse resistance to chemotherapy in triple negative breast cancer that has spread or come back. It aims to help your body respond better to treatment.
ShanghaiAges 18–70 - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70 - NCT06559540RecruitingPhase 2
Compare short radiation courses for node-positive breast cancer
This study compares two shorter courses of radiation therapy for women with node-positive breast cancer. It aims to see if an ultra-short course is as safe and effective as the slightly longer short course.
St Louis, MissouriAges 18 years+ - NCT06690840RecruitingPhase 2
Atezolizumab plus chemo for advanced triple-negative breast cancer
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
Monza, MonzaAges 18 years+ - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT06845319RecruitingPhase 2
Chemo-immunotherapy before surgery for triple-negative breast cancer
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
Charleston, South CarolinaAges 18 years+ - NCT07017673RecruitingPhase 2
Ivonescimab with chemo for early-stage triple negative breast cancer
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
Los Angeles, CaliforniaAges 18 years+ - NCT07045311RecruitingPhase 2
JS207 combination therapy for triple-negative breast cancer
This trial tests a new combination treatment for people with advanced triple-negative breast cancer who have not yet received treatment for their advanced disease. It aims to see if the combination can help shrink or control the cancer.
Hefei, AnhuiAges 18–75 - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT07319195RecruitingEarly Phase 1
Study of a new drug injected into tumors for breast cancer
This trial tests a drug called mitazalimab injected directly into the tumor for patients with early-stage or recurrent breast cancer who are scheduled for surgery. The goal is to see if this approach can help the immune system fight the cancer before surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07457359RecruitingPhase 2
Toripalimab plus radiation for chemo-resistant triple-negative breast cancer
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
HangzhouAges 18–75 - NCT06791161Enrolling by invitation
Adjuvant therapy study for BRCA1/2 positive breast cancer
This study tests if additional treatment after surgery helps prevent breast cancer from returning. It is for people with hormone receptor-positive, HER2-negative breast cancer who have a BRCA1 or BRCA2 gene mutation and a high risk of recurrence.
Beijing, Beijing MunicipalityAges 18–75 - NCT07011654RecruitingPhase 1/Phase 2
Study of two drugs for metastatic triple-negative breast cancer
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT03646955Recruiting
Partial breast radiation versus no radiation after lumpectomy
This trial compares giving radiation only to part of the breast versus not giving radiation at all after breast-conserving surgery. It’s meant for women with early, hormone-driven breast cancer to see if skipping radiation can be safe and reduce treatment burden.
SantiagoAges 60 years+ - NCT06938724RecruitingPhase 2
Avoiding extra surgery in women with HER2+ or triple-negative breast cancer
This trial tests whether women with HER2-positive or triple-negative breast cancer who had a complete response to chemotherapy can safely skip radiation or additional surgery. If you had a complete tumor response after chemo and had breast-conserving surgery, you may be eligible.
MilanAges 18 years+
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 + breast cancer?
- Yes. Clin2 currently lists 956 recruiting her2 + breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 + breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.